A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.

Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay L, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA.

Open source

DOI
10.1080/14796694.2024.2442851
Published
2025-01-14
Container
Future Oncol
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2024.2442851,
  title = {A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.},
  author = {Schadendorf D and  Dummer R and  Flaherty KT and  Robert C and  Arance A and  de Groot JWB and  Garbe C and  Gogas HJ and  Gutzmer R and  Krajsová I and  Liszkay L and  Loquai C and  Mandalà M and  Yamazaki N and  Queirolo P and  Guenzel C and  Polli A and  Thakur M and  di Pietro A and  Ascierto PA.},
  year = {2025},
  journal = {Future Oncol},
  doi = {10.1080/14796694.2024.2442851},
  url = {https://doi.org/10.1080/14796694.2024.2442851}
}

RIS

TY  - JOUR
TI  - A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
AU  - Schadendorf D
AU  -  Dummer R
AU  -  Flaherty KT
AU  -  Robert C
AU  -  Arance A
AU  -  de Groot JWB
AU  -  Garbe C
AU  -  Gogas HJ
AU  -  Gutzmer R
AU  -  Krajsová I
AU  -  Liszkay L
AU  -  Loquai C
AU  -  Mandalà M
AU  -  Yamazaki N
AU  -  Queirolo P
AU  -  Guenzel C
AU  -  Polli A
AU  -  Thakur M
AU  -  di Pietro A
AU  -  Ascierto PA.
PY  - 2025
JO  - Future Oncol
DO  - 10.1080/14796694.2024.2442851
UR  - https://doi.org/10.1080/14796694.2024.2442851
ER  - 

APA

D, S., R, D., KT, F., C, R., A, A., JWB, D. G., C, G., HJ, G., R, G., I, K., L, L., C, L., M, M., N, Y., P, Q., C, G., A, P., M, T., A, D. P., & PA., A. (2025). A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.. Future Oncol. https://doi.org/10.1080/14796694.2024.2442851

Source records